According to the 2019 European Society of Cardiology Guidelines for the management of chronic coronary syndromes, ACE inhibitors are recommended for the treatment of patients with chronic coronary syndromes comorbid with hypertension, left ventricular ejection fraction ≤ 40%, diabetes, or chronic kidney disease unless contraindicated [10]. The gene discussed is ACE; the disease is chronic kidney disease.